FGA
INDV icon

Fortis Group Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Fortis Group Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Hold
17
– – ﹤0.01% 568
2026
Q1 		$518 Hold
17
– – ﹤0.01% 544
2025
Q4 		$610 Hold
17
– – ﹤0.01% 533
2025
Q3 		$410 Hold
17
– – ﹤0.01% 497
2025
Q2 		$251 Hold
17
– – ﹤0.01% 498
2025
Q1 		$162 Hold
17
– – ﹤0.01% 474
2024
Q4 		$211 Hold
17
– – ﹤0.01% 480
2024
Q3 		$166 Hold
17
– – ﹤0.01% 477
2024
Q2 		$274 Hold
17
– – ﹤0.01% 474
2024
Q1 		$364 Sell
17
-17
-50% -$319 ﹤0.01% 483
2023
Q4 		$520 Buy
34
+17
+100% +$302 ﹤0.01% 425
2023
Q3 		$392 Buy
+17
New +$388 ﹤0.01% 417

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortis Group Advisors's INDV Position: Q2 2026 in Review

Fortis Group Advisors held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 17 shares worth $698. The position accounts for ﹤0.01% of the portfolio, ranked #568.

Fortis Group Advisors first reported a position in INDV in Q3 2023 and has held it in 12 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Fortis Group Advisors held 17 shares of Indivior Pharmaceuticals worth $698 as of Q2 2026.
  • Fortis Group Advisors left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Fortis Group Advisors's portfolio in Q2 2026, its #568 holding.
  • Fortis Group Advisors first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Fortis Group Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.